※ 관련근거 ․AHFS Drug Information (2006) p.3742 ․Cinical Oncology 3rd (2004) p.1635 ․NCCN Clinical Practice Guidelines in Oncology V.3.2017, Neuroendocrine Tumors ․Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide, Annals of Oncology 11:1127-1130, 2000 · Harrison's Principles of Internal Medicine, 20e · Comprehensive Clinical Nephrology, 6th ed, 2019 · Current Diagnosis & Treatment: Emergency Medicine, 8e, 2017 · Pharmacotherapy: A pathophysiologic Approach, 10e, 2017 · KDIGO Anemia in Chronic Kidney Disease, 2012 · Chronic kidney disease: managing anaemia. NICE guideline Published: 3 June 2015 · Mikhail A et al. Renal association clinical practice guideline on anaemia od Chronic Kidney Disease, BMC Nephrology (2017) 18:345 · Locatelli F et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice(ERBP), 2008 · Yamamoto H et al. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease · Collister D, Komenda P et al. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med. 2016 Apr 5;164(7):472-8. · Palmer SC, Saglimbene V et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014 Dec 8;(12):CD010590. · Johansen KL, Finkelstein FO et al. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant. 2012 Jun;27(6):2418-25. · Palmer SC, Navaneethan SD et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010 Jul 6;153(1):23-33. · Inrig JK, Barnhart HX et al. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep;60(3):390-401.
· Patel M, Thimons DG et al. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. J Am Med Dir Assoc. 2012 Mar;13(3):244-8. |